Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists

Area of Science:

• Medicinal Chemistry
• Immunology
• Drug Discovery

Background:

• Nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) is a key immune receptor.
• Desmuramylpeptides are agonists that modulate NOD2 activity.
• Understanding structure-activity relationships is crucial for developing targeted therapeutics.

Purpose of the Study:

• To design, synthesize, and evaluate novel desmuramylpeptide NOD2 agonists.
• To delineate structural requirements for physicochemical and immunomodulatory properties.
• To explore the therapeutic potential of these compounds in various immune contexts.

Main Methods:

• Chemical synthesis of a series of desmuramylpeptide derivatives.
• In vitro biological evaluation of NOD2 agonism using EC50 determination.
• Assessment of immunomodulatory activities in peripheral blood mononuclear cells (PBMCs) and bone marrow-derived dendritic cells (BMDCs).

Main Results:

• Compound 3, a butyrylated desmuramylpeptide, exhibited potent in vitro NOD2 agonism (EC50 = 4.6 nM), a 17-fold improvement over compound 1.
• Novel desmuramylpeptides elicited cytokine production in PBMCs, alone and with LPS.
• Specific derivatives showed enhanced cytotoxic activity against cancer cells (compound 32), anti-inflammatory effects (compound 26), and augmented antigen presentation for vaccine adjuvant potential (compound 23).

Conclusions:

• Structural modifications significantly enhance NOD2 agonist potency and modulate immunomodulatory profiles.
• Novel desmuramylpeptides offer diverse therapeutic applications, including anti-inflammatory agents and vaccine adjuvants.
• This study provides a foundation for developing targeted NOD2-modulating therapies.